Viveve Medical (NASDAQ:VIVE) is set to issue its quarterly earnings data after the market closes on Thursday, March 15th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter.
Shares of Viveve Medical (NASDAQ VIVE) traded up $0.03 during midday trading on Tuesday, hitting $4.25. The stock had a trading volume of 149,356 shares, compared to its average volume of 284,554. Viveve Medical has a twelve month low of $3.30 and a twelve month high of $11.16. The stock has a market capitalization of $131.40, a P/E ratio of -1.98 and a beta of -0.79. The company has a debt-to-equity ratio of 2.72, a quick ratio of 3.63 and a current ratio of 3.89.
VIVE has been the subject of several analyst reports. Mizuho initiated coverage on Viveve Medical in a report on Thursday, November 16th. They set a “buy” rating and a $10.00 target price for the company. ValuEngine downgraded Viveve Medical from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Northland Securities initiated coverage on Viveve Medical in a report on Friday, January 5th. They set an “outperform” rating and a $8.00 target price for the company. Finally, Ladenburg Thalmann Financial Services reaffirmed a “buy” rating on shares of Viveve Medical in a report on Thursday, January 4th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $10.00.
An institutional investor recently bought a new position in Viveve Medical stock. State Street Corp acquired a new position in Viveve Medical Inc (NASDAQ:VIVE) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 178,606 shares of the company’s stock, valued at approximately $1,282,000. State Street Corp owned approximately 0.92% of Viveve Medical at the end of the most recent quarter. 40.60% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Viveve Medical (VIVE) Set to Announce Earnings on Thursday” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://ledgergazette.com/2018/03/13/viveve-medical-vive-set-to-announce-earnings-on-thursday.html.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.